MOLECULIN BIOTECH INC (MBRX) Stock Price, Quote, News and Overview
NASDAQ:MBRX - Nasdaq - US60855D3098 - Common Stock - Currency: USD
MBRX Quote, Performance and Key Statistics
MOLECULIN BIOTECH INC
NASDAQ:MBRX (2/12/2025, 8:25:49 PM)
After market: 0.42 0 (0%)0.42
-0.09 (-17.24%)
The current stock price of MBRX is 0.42 USD. In the past month the price decreased by -77.54%. In the past year, price decreased by -94.37%.
MBRX Latest News and Analysis
Unusual volume stocks in Wednesday's session
Discover the stocks with unexpected trading volume in today's session on the US markets.
MBRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.07 | 341.06B | ||
| AMGN | AMGEN INC | 14.89 | 158.60B | ||
| GILD | GILEAD SCIENCES INC | 22.41 | 128.75B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1562.76 | 116.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 72.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.82B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.80B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| BIIB | BIOGEN INC | 8.17 | 19.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.28 | 16.55B |
Related stock screener links
About MBRX
Company Profile
Moleculin Biotech Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 18 full-time employees. The company went IPO on 2016-06-02. Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The firm has a pipeline of clinical programs for the treatment of tumors and viruses. The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Company Info
MOLECULIN BIOTECH INC
5300 Memorial Dr Ste 950
Houston TEXAS 77007 US
CEO: Walter V. Klemp
Employees: 18
Company Website: https://moleculin.com/
Investor Relations: http://moleculin.com/investors/
Phone: 17133005160
MBRX FAQ
What is the stock price of MBRX?
The current stock price of MBRX is 0.42 USD.
What is the symbol for MOLECULIN BIOTECH INC stock?
The exchange symbol of MOLECULIN BIOTECH INC is MBRX and it is listed on the Nasdaq exchange.
On which exchange is MBRX stock listed?
MBRX stock is listed on the Nasdaq exchange.
Is MBRX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for MBRX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of MBRX.
Does MBRX stock pay dividends?
MBRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of MBRX?
MBRX does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.59).
What is the Short Interest ratio of MBRX stock?
The outstanding short interest for MBRX is 5.86% of its float.
MBRX Technical Analysis
MBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MBRX. The financial health of MBRX is average, but there are quite some concerns on its profitability.
MBRX Financial Highlights
Over the last trailing twelve months MBRX reported a non-GAAP Earnings per Share(EPS) of -11.59. The EPS decreased by 14.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -128.88% | ||
| ROE | -403.13% | ||
| Debt/Equity | 0 |
MBRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to MBRX. The Buy consensus is the average rating of analysts ratings from 8 analysts.